ES2982489T3 - Composiciones para el tratamiento de afecciones que utilizan virus adeno-asociados recombinantes autocomplementarios - Google Patents
Composiciones para el tratamiento de afecciones que utilizan virus adeno-asociados recombinantes autocomplementarios Download PDFInfo
- Publication number
- ES2982489T3 ES2982489T3 ES17842207T ES17842207T ES2982489T3 ES 2982489 T3 ES2982489 T3 ES 2982489T3 ES 17842207 T ES17842207 T ES 17842207T ES 17842207 T ES17842207 T ES 17842207T ES 2982489 T3 ES2982489 T3 ES 2982489T3
- Authority
- ES
- Spain
- Prior art keywords
- raav
- gene
- composition
- vector
- cartilage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title description 13
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 58
- 239000013598 vector Substances 0.000 claims abstract description 51
- 208000024891 symptom Diseases 0.000 claims abstract description 32
- 238000002347 injection Methods 0.000 claims abstract description 23
- 239000007924 injection Substances 0.000 claims abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 20
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 32
- 210000000845 cartilage Anatomy 0.000 claims description 22
- 210000000234 capsid Anatomy 0.000 claims description 20
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 19
- 210000001612 chondrocyte Anatomy 0.000 claims description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 16
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 210000002437 synoviocyte Anatomy 0.000 claims description 11
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 10
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 9
- 108010006025 bovine growth hormone Proteins 0.000 claims description 8
- 239000003862 glucocorticoid Substances 0.000 claims description 8
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 7
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 7
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims description 7
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 6
- 239000000018 receptor agonist Substances 0.000 claims description 6
- 229940044601 receptor agonist Drugs 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 230000008488 polyadenylation Effects 0.000 claims description 5
- 230000008439 repair process Effects 0.000 claims description 5
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 4
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 4
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 4
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 4
- 210000000281 joint capsule Anatomy 0.000 claims description 4
- 210000003041 ligament Anatomy 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 210000001258 synovial membrane Anatomy 0.000 claims description 4
- 210000002435 tendon Anatomy 0.000 claims description 4
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 3
- 229940099552 hyaluronan Drugs 0.000 claims description 3
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 2
- 241000649045 Adeno-associated virus 10 Species 0.000 claims description 2
- 241000649046 Adeno-associated virus 11 Species 0.000 claims description 2
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 4
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 4
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 238000013519 translation Methods 0.000 abstract description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 abstract 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 abstract 2
- 102000000589 Interleukin-1 Human genes 0.000 description 57
- 108010002352 Interleukin-1 Proteins 0.000 description 57
- 150000007523 nucleic acids Chemical group 0.000 description 24
- 230000001225 therapeutic effect Effects 0.000 description 14
- 210000003127 knee Anatomy 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 241000701022 Cytomegalovirus Species 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229940037128 systemic glucocorticoids Drugs 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000005065 subchondral bone plate Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 208000008558 Osteophyte Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000010934 exostosis Diseases 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229940054136 kineret Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010058112 Chondrolysis Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 102000046824 human IL1RN Human genes 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108091004583 lutikizumab Proteins 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377297P | 2016-08-19 | 2016-08-19 | |
| PCT/US2017/047589 WO2018035451A1 (en) | 2016-08-19 | 2017-08-18 | Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2982489T3 true ES2982489T3 (es) | 2024-10-16 |
Family
ID=61197123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17842207T Active ES2982489T3 (es) | 2016-08-19 | 2017-08-18 | Composiciones para el tratamiento de afecciones que utilizan virus adeno-asociados recombinantes autocomplementarios |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11207382B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3500278B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7165410B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20230130155A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109843306A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017313844B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3073137A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2982489T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018035451A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11207382B2 (en) | 2016-08-19 | 2021-12-28 | University Of Florida Research Foundation, Incorporated | Compositions for treating conditions using recombinant self-complementary adeno-associated virus |
| AU2017371043B2 (en) * | 2016-12-07 | 2022-12-15 | University Of Florida Research Foundation, Incorporated | IL-1Ra cDNAs |
| DK3740222T5 (da) | 2018-01-17 | 2024-08-26 | Meiragtx Uk Ltd | Modificeret RAAV-capsidprotein til genterapi |
| US12370240B2 (en) | 2018-11-28 | 2025-07-29 | Genascence Corporation | Methods and compositions for treating osteoarthritis |
| KR20210126096A (ko) | 2019-02-15 | 2021-10-19 | 상가모 테라퓨틱스, 인코포레이티드 | 재조합 aav를 제조하기 위한 조성물 및 방법 |
| CA3146791A1 (en) * | 2019-07-15 | 2021-01-21 | Meiragtx Uk Ii Limited | Modified aav capsid proteins for treatment of arthritic disease |
| WO2021138559A1 (en) * | 2019-12-31 | 2021-07-08 | Swanbio Therapeutics Limited | Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn) |
| WO2025049993A1 (en) | 2023-08-31 | 2025-03-06 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156304A (en) | 1990-12-20 | 2000-12-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for studying and treating a connective tissue of a mammalian host |
| US5747072A (en) | 1993-07-30 | 1998-05-05 | University Of Michigan | Adenoviral-mediated gene transfer to synovial cells in vivo |
| WO1995016353A1 (en) * | 1993-12-14 | 1995-06-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Systemic gene treatment of connective tissue diseases |
| US5756283A (en) | 1995-06-05 | 1998-05-26 | The Trustees Of The University Of Pennsylvania | Method for improved production of recombinant adeno-associated viruses for gene therapy |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
| US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| AU728220B2 (en) | 1997-04-14 | 2001-01-04 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
| AU9319198A (en) | 1997-09-19 | 1999-04-05 | Trustees Of The University Of Pennsylvania, The | Methods and vector constructs useful for production of recombinant aav |
| WO1999049029A1 (en) | 1998-03-20 | 1999-09-30 | Benitec Australia Ltd | Control of gene expression |
| WO2000028004A1 (en) | 1998-11-10 | 2000-05-18 | The University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| ES2312344T3 (es) | 1999-05-28 | 2009-03-01 | Targeted Genetics Corporation | Metodos y composiciones para disminuir el nivel de factor de necrosis tumoral (tnf) en trastornos asociados con tnf. |
| AU3459701A (en) | 2000-01-26 | 2001-08-07 | Chiron Corporation | Recombinant aav packaging systems |
| CA2410828C (en) | 2000-06-01 | 2012-01-24 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| DE10056210A1 (de) | 2000-11-13 | 2002-05-29 | Arimedes Biotechnology Gmbh | Virales Expressionssystem |
| WO2002062375A1 (en) * | 2001-02-06 | 2002-08-15 | Merck Patent Gmbh | Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
| KR100472297B1 (ko) | 2001-09-27 | 2005-03-07 | 주식회사 두산 | 리소인지질의 수용성 조성물 |
| KR100471942B1 (ko) | 2002-03-19 | 2005-03-09 | 주식회사 에스원 | 복합형 카드와 카드정보 등록 제어시스템 |
| DE10318048A1 (de) | 2003-04-17 | 2004-11-04 | Axaron Bioscience Ag | Nicht fluoreszierende, durch Proteolyse zur Fluoreszenz aktivierbare Reporterproteine und ihre Verwendung zur Detektion Protease-abhängiger Ereignisse |
| NZ545656A (en) | 2003-09-01 | 2009-02-28 | Amc Amsterdam | AAV vectors for in vivo gene therapy of rheumatoid arthritis |
| US20070009899A1 (en) | 2003-10-02 | 2007-01-11 | Mounts William M | Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases |
| US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
| EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| US7943374B2 (en) * | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| FR2891544A1 (fr) | 2005-09-30 | 2007-04-06 | Genethon Ass Loi De 1901 | Substrat proteique pour la detection de l'activite calpaine 3 |
| WO2007112001A2 (en) | 2006-03-23 | 2007-10-04 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Compositions and methods for treating myocardial infarction |
| EP2037943A4 (en) | 2006-04-21 | 2010-03-31 | Univ North Carolina | TREATMENT OF BIND WEB DISEASES |
| US20080187576A1 (en) * | 2006-06-16 | 2008-08-07 | University Of Florida Research Foundation, Inc. | Methods for treating articular disease or dysfunction using self-complimentary adeno-associated viral vectors |
| US20080166762A1 (en) | 2006-09-27 | 2008-07-10 | Reliance Life Science Pvt.Ltd. | HETEROLOGOUS PRODUCTION OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (IL-1Ra) IN PICHIA PASTORIS |
| US7452696B2 (en) | 2006-10-27 | 2008-11-18 | National Taiwan University | Recombinant plasmid and method for expressing hepatitis B viral antigens and virions in vivo |
| JP5575486B2 (ja) | 2007-01-18 | 2014-08-20 | ユニヴァーシティ オブ ミズーリー−コロンビア | 筋鞘にｎＮＯＳを回復させる合成ミニ／ミクロジストロフィン遺伝子 |
| GB0708376D0 (en) | 2007-05-01 | 2007-06-06 | Alligator Bioscience Ab | Novel polypeptides and uses thereof |
| KR101667069B1 (ko) * | 2008-11-17 | 2016-10-17 | 이노비오 파마수티컬즈, 인크. | 플라비바이러스에 대한 면역반응을 유발하는 항원 및 이를 사용하는 방법 |
| US9610363B2 (en) | 2009-04-16 | 2017-04-04 | President And Fellows Of Harvard College | Methods for inhibiting starvation of a cell |
| BR112012007114A2 (pt) | 2009-09-29 | 2016-07-05 | Gilead Biologics Inc | métodos e composições para tratamento da fibrose ocular |
| DE202009017772U1 (de) | 2009-12-10 | 2011-04-21 | Orthogen Ag | Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid |
| EP2394667A1 (en) | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
| WO2012047093A1 (en) | 2010-10-05 | 2012-04-12 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Treatment of the sjögren's syndrome |
| US8883134B2 (en) * | 2010-10-20 | 2014-11-11 | Handok Pharmaceuticals, Inc. | Human interleukin-1 receptor antagonist—hybrid Fc fusion protein |
| US8736207B2 (en) | 2011-01-03 | 2014-05-27 | General Electric Company | Method and system for power conversion |
| CN103596591B (zh) | 2011-02-08 | 2016-08-24 | Abbvie公司 | 骨关节炎和疼痛的治疗 |
| US20130021786A1 (en) | 2011-07-21 | 2013-01-24 | Noble Matthew D | Utility bag lighting |
| ES2534782T3 (es) | 2012-02-02 | 2015-04-28 | Baylor College Of Medicine | Sistema biológico de administración y expresión basado en adenovirus para uso en el tratamiento de la osteoartritis |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9254311B2 (en) * | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| EP2660325A3 (en) | 2012-05-02 | 2014-02-12 | Christian Medical College | AAV vectors and corresponding nucleotide sequences and methods |
| CN103509100B (zh) | 2012-06-15 | 2017-10-27 | 上海百迈博制药有限公司 | 一种白细胞介素‑1受体拮抗剂突变体 |
| US9624282B2 (en) | 2012-11-26 | 2017-04-18 | The Curators Of The University Of Missouri | Microdystrophin peptides and methods for treating muscular dystrophy using the same |
| ES2802878T3 (es) | 2013-01-25 | 2021-01-21 | Baylor College Medicine | Un sistema de administración y expresión de terapia génica adenoviral dependiente de linfocitos T colaboradores |
| EP2792742A1 (en) | 2013-04-17 | 2014-10-22 | Universitätsklinikum Hamburg-Eppendorf (UKE) | Gene-therapy vectors for treating cardiomyopathy |
| CN105682674A (zh) | 2013-04-17 | 2016-06-15 | 建新公司 | 用于治疗和预防黄斑变性的组合物和方法 |
| DE102013215817A1 (de) | 2013-08-09 | 2015-02-12 | Universitätsklinikum Hamburg-Eppendorf | Neue peptide mit spezifität für die lunge |
| ES2936220T3 (es) | 2013-08-27 | 2023-03-15 | Res Inst Nationwide Childrens Hospital | Productos y métodos para el tratamiento de la esclerosis lateral amiotrófica |
| EP3068889B1 (en) | 2013-09-26 | 2019-04-17 | Universitat Autònoma De Barcelona | Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease |
| DE102013220859B4 (de) | 2013-10-15 | 2016-09-08 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit viralen Expressionskassetten und ihre Verwendung zur Transformation von Zellen zur Erzeugung rekombinanter Viren oder viraler Genvektoren |
| WO2015160893A1 (en) | 2014-04-15 | 2015-10-22 | Applied Genetic Technologies Corporation | Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) |
| DE102014207498A1 (de) | 2014-04-17 | 2015-10-22 | Universitätsklinikum Hamburg-Eppendorf | Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark |
| IL248102B (en) | 2014-05-02 | 2022-07-01 | Genzyme Corp | aav vectors for gene therapy of the central nervous system and retina |
| US11207382B2 (en) | 2016-08-19 | 2021-12-28 | University Of Florida Research Foundation, Incorporated | Compositions for treating conditions using recombinant self-complementary adeno-associated virus |
| WO2018035457A1 (en) | 2016-08-19 | 2018-02-22 | Calimmune, Inc. | Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus |
| US20200318080A1 (en) | 2016-08-19 | 2020-10-08 | Colorado State University Research Foundation | Methods and compositions for treating equine conditions using recombinant self-complementary adeno-associated virus |
| AU2017371043B2 (en) | 2016-12-07 | 2022-12-15 | University Of Florida Research Foundation, Incorporated | IL-1Ra cDNAs |
-
2017
- 2017-08-18 US US16/326,488 patent/US11207382B2/en active Active
- 2017-08-18 WO PCT/US2017/047589 patent/WO2018035451A1/en not_active Ceased
- 2017-08-18 KR KR1020237029234A patent/KR20230130155A/ko not_active Ceased
- 2017-08-18 AU AU2017313844A patent/AU2017313844B2/en active Active
- 2017-08-18 JP JP2019530369A patent/JP7165410B2/ja active Active
- 2017-08-18 EP EP17842207.7A patent/EP3500278B1/en active Active
- 2017-08-18 CA CA3073137A patent/CA3073137A1/en active Pending
- 2017-08-18 KR KR1020197007510A patent/KR102759317B1/ko active Active
- 2017-08-18 CN CN201780061659.XA patent/CN109843306A/zh active Pending
- 2017-08-18 ES ES17842207T patent/ES2982489T3/es active Active
-
2021
- 2021-12-17 US US17/555,320 patent/US20220175887A1/en active Pending
-
2022
- 2022-07-11 JP JP2022111264A patent/JP7653150B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190381140A1 (en) | 2019-12-19 |
| KR20230130155A (ko) | 2023-09-11 |
| US11207382B2 (en) | 2021-12-28 |
| JP7165410B2 (ja) | 2022-11-04 |
| JP7653150B2 (ja) | 2025-03-28 |
| EP3500278C0 (en) | 2024-05-22 |
| CA3073137A1 (en) | 2018-02-22 |
| EP3500278A1 (en) | 2019-06-26 |
| KR102759317B1 (ko) | 2025-01-31 |
| JP2022130745A (ja) | 2022-09-06 |
| WO2018035451A1 (en) | 2018-02-22 |
| EP3500278B1 (en) | 2024-05-22 |
| US20220175887A1 (en) | 2022-06-09 |
| EP3500278A4 (en) | 2020-04-01 |
| AU2017313844A1 (en) | 2019-04-11 |
| KR20190055086A (ko) | 2019-05-22 |
| AU2017313844B2 (en) | 2023-10-12 |
| JP2019524890A (ja) | 2019-09-05 |
| CN109843306A (zh) | 2019-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2982489T3 (es) | Composiciones para el tratamiento de afecciones que utilizan virus adeno-asociados recombinantes autocomplementarios | |
| JP7629584B2 (ja) | 哺乳動物の変形性関節症及び関連する関節症状の治療に有用なｈａｓ２及びルブリシンを含む骨保護遺伝子を発現する組換えａａｖベクター | |
| ES2830440T3 (es) | Uso de inhibidores de miostatina y terapias combinadas | |
| ES2685611T3 (es) | Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo | |
| US20150139952A1 (en) | Methods, compositions, cells, and kits for treating ischemic injury | |
| US11958886B2 (en) | IL-1RA cDNAs | |
| US20200318080A1 (en) | Methods and compositions for treating equine conditions using recombinant self-complementary adeno-associated virus | |
| JP2022517435A (ja) | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 | |
| Payne et al. | Single intra-articular injection of adeno-associated virus results in stable and controllable in vivo transgene expression in normal rat knees | |
| JP7575273B2 (ja) | デュシェンヌ型筋ジストロフィーを治療するための組成物及び方法 | |
| JP2024527742A (ja) | アデノ随伴ウイルス粒子及びその使用方法 | |
| KR20240063110A (ko) | 치료제의 역행성 관상 정맥 또는 정맥동 투여 | |
| US20210283222A1 (en) | Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus | |
| KR20200013674A (ko) | 허혈 조직을 치료하는 방법 | |
| US20250115659A1 (en) | Novel proteins and nucleic acid sequences and use thereof in the prophylaxis and/or treatment of congenital muscular dystrophies | |
| US20200113972A1 (en) | Vegf gene therapy for tendon and ligament injuries | |
| BR112020021179B1 (pt) | Proteína mutante recombinante da superfamília da distrofina, vírus adeno-associado recombinante e seus usos | |
| Ghivizzani et al. | Gene therapy for osteoarthritis | |
| HK40049102B (zh) | 用於治疗杜兴肌营养不良的组合物和方法 | |
| Danialou et al. | Gene Therapy for the Respiratory Muscles | |
| Myogenic | 150. AAV Microgene Transfer Reveals the Cellular Motif for Dystrophin-Mediated Sarcolemmal Neuronal Nitric Oxide Synthase (nNOS) Localization |